Edmund Jessop | Medical Adviser
National Health Service

Edmund Jessop, Medical Adviser, National Health Service

Edmund Jessop has been practising public health for the NHS in England since 1981 in various jobs at district, regional and national levels. Since 2002, he has been medical adviser to the team which plans, funds and monitors services for patients with very rare disease. This has included decision making, and more recently close liaison with NICE, on the so-called “ultra-orphan” drugs as well as other highly specialised technologies. Edmund is UK representative to the EU Expert Group on Rare Disease. 

He was Vice President of the UK Faculty of Public Health (FPH) from 2011 to 2014 and Editor of the Journal of Public Health 1998 - 2007. He has taught courses on public health including health economics and health technology assessment for over 15 years.


World Orphan Drug Congress USA 2018 - Conference Day Two @ 11:40

Drug pricing in Europe, improving the role of HTA agencies and looking into the sustainability of managed access agreements

  • Looking into voluntary price joint price negotiations as a means to assess highly priced drugs and increase access
  • Can HTA assessment be improved across European countries? 
  • What will be the future of managed access agreements as more drugs require them and more resources are needed? Can this model be replicated around Europe?

back to speakers